Regenerative approaches such as platelet-rich plasma (PRP) and stem cell injections aim to calm inflammation and support a joint’s own repair processes, rather than surgically replacing worn cartilage. For degenerative arthritis the evidence is still evolving: current trials point to modest symptom relief, not cure, and any decision should follow an individual clinical assessment.
Can stem cell injections treat arthritis?
Stem cell injections are being studied as a way to ease pain and improve function in arthritic joints, but they are not an established cure and do not regrow lost cartilage on demand. They are best understood as one investigational option, considered case by case alongside proven conservative care.
Osteoarthritis is the most common form of arthritis and one of the largest sources of chronic pain worldwide. According to the World Health Organization, about 528 million people were living with osteoarthritis in 2019 — an increase of 113% since 1990 — and 73% of those affected were older than 55. For most of these people the condition is a slow, degenerative thinning of joint cartilage rather than a single dramatic injury.
That distinction matters. Much of the public interest in regenerative injections comes from sport, where the aim is to speed recovery from an acute tear or strain in an otherwise healthy joint. Degenerative arthritis is a different clinical picture: cumulative wear, low-grade inflammation and structural change that has often developed over years. The questions worth asking about regenerative options are therefore different too, and the honest answer to several of them is still “we are learning.”
How do regenerative approaches differ from joint replacement?
Regenerative injections work biologically — introducing cells or concentrated blood-derived factors that may modulate inflammation and signalling inside the joint. Joint replacement is a mechanical solution that removes and resurfaces the damaged joint entirely.
Conventional management of osteoarthritis follows a familiar ladder: weight management and exercise, physiotherapy, oral analgesics and anti-inflammatories, corticosteroid or hyaluronic acid injections, and — where pain and disability become severe — surgery, up to and including total joint replacement. These steps are well established and, for the right patient, highly effective.
Regenerative approaches sit in a different conceptual space. Rather than resurfacing or replacing the joint, they attempt to influence the joint’s biological environment. PRP concentrates platelets and growth factors from a patient’s own blood; cell-based therapies introduce mesenchymal cells that are thought to release anti-inflammatory and signalling molecules. The proposed mechanism is less “rebuild the cartilage” and more “quieten the inflammatory process and support the tissue that remains.” That is an important nuance, because it sets realistic expectations: these are not a way to reverse advanced joint destruction, and they are not a substitute for surgery when surgery is genuinely indicated.
What does the evidence actually show?
The evidence is best described as promising but immature, especially for arthritis specifically. Some trials report meaningful symptom relief; the overall certainty of that evidence remains low, and much of the measured benefit may reflect the natural history of the condition and placebo effects.
A broad review of stem cell injections for knee osteoarthritis pooled 25 randomised trials involving 1,341 participants. Its conclusion, published via the US National Library of Medicine, was measured: stem cell injections “may slightly improve pain and function,” but the certainty of the evidence was graded low, most trials were small, and effects on the joint’s structure and on long-term safety were not established. In plain terms, the signal is real but modest, and the research base is not yet robust enough to promise outcomes.
PRP has a slightly longer clinical track record. A 2025 narrative review found that PRP tends to outperform hyaluronic acid and placebo for pain and function, with the clearest benefit in mild-to-moderate osteoarthritis. But the same literature is undermined by inconsistency: preparation protocols, platelet concentrations and injection schedules vary enormously between studies, which makes results hard to compare. A separate meta-research study found that roughly 84% of systematic reviews on PRP for osteoarthritis were of critically-low methodological quality. We think patients deserve to hear that plainly rather than have it smoothed over.
The reasonable summary: these therapies are generally well tolerated, they may help symptoms in earlier-stage disease, and they are not miracle cures. Anyone promising guaranteed cartilage regrowth is going beyond what the science supports.
Is this the same as recovering from a sports injury?
No. Athletic recovery targets an acute injury in a young, otherwise healthy joint, whereas degenerative arthritis involves chronic, cumulative change — a different goal and a different evidence picture.
If your situation is an acute tendon, ligament or muscle injury rather than long-standing joint wear, the considerations are genuinely different, and the research and protocols that apply to athletes may be more relevant to you. For that readership we cover the acute and performance angle separately in our sports injury programme for athletes. This article stays deliberately focused on ordinary degenerative joint pain — the aching knees, hips and hands that accumulate with age.
Who might be a reasonable candidate to discuss this with a clinician?
The most plausible candidates are people with mild-to-moderate osteoarthritis whose symptoms persist despite conservative care, who understand the evidence is still developing, and who are not yet at the point where surgery is clearly indicated. It is a conversation to have, not a treatment to demand.
Family members researching options for an older relative should approach the topic with the same balance. Regenerative injections are unlikely to help someone with severe, bone-on-bone arthritis for whom joint replacement is the appropriate step, and they are not a way to avoid a surgery that is genuinely needed. Where they may have a role is earlier in the disease, as part of a broader plan that still includes exercise, weight management and physiotherapy. The only responsible way to know is an individual assessment: imaging, a review of previous treatments, and an honest discussion of what the current evidence can and cannot promise.
What about PRP for degenerative joint pain?
PRP uses a patient’s own concentrated platelets and is among the more studied regenerative options for osteoarthritis. It may help pain and function in earlier-stage disease, though results vary and preparation methods are not standardised across the field.
Because PRP is autologous — derived from the patient’s own blood — its safety profile in the published literature is favourable, which is one reason it is often discussed before cell-based therapies. It is still not a cure, and the same caveats about evidence quality apply. What good practice looks like is careful patient selection, clear expectations, and integration with the rest of a joint-care plan rather than PRP as a stand-alone promise.
Joint Regeneration at Holina Clinic
At Holina Clinic we offer PRP therapy and stem cell therapy as established services, delivered on-site at our two campuses on Koh Phangan and at Khao Yai. We do not treat these as off-the-shelf products. Every enquiry begins with an individualised diagnostic assessment — imaging, clinical history and a review of what has already been tried — so that any recommendation reflects the specific joint, the stage of disease and the person in front of us.
Our position on regenerative options for degenerative joint pain is deliberately conservative. We present the current state of the evidence honestly, including its limitations, and we will say plainly when we believe conservative care or a surgical referral is the more appropriate path. Where a regenerative approach is a reasonable option, we integrate it into a wider plan rather than offering it in isolation.
“With degenerative arthritis, the most useful thing we can offer is honesty. Regenerative injections may help some people with earlier-stage joint disease, but they are not a cure and they are not right for everyone. Our role is to assess each joint individually and to recommend only what the evidence and the patient’s own situation genuinely support,” says Dr. Natalie Lindemann, Clinical Director (Global) at Holina Global.
If you or a family member are weighing options for ongoing joint pain, you are welcome to speak with our clinical team to arrange an assessment.
Frequently asked questions
Are stem cell injections a cure for arthritis?
No. Current evidence suggests they may modestly improve pain and function in some people, but they are not a cure and do not reliably regrow lost cartilage.
Is there good scientific evidence that they work?
The evidence is still developing. A review of 25 randomised trials found only low-certainty evidence of a slight benefit for knee osteoarthritis, so results should be interpreted cautiously.
What is the difference between PRP and stem cell therapy?
PRP concentrates platelets and growth factors from your own blood, while stem cell therapy introduces cells thought to release anti-inflammatory and signalling molecules. Both aim to influence the joint’s biology rather than replace it.
Can these injections help me avoid joint replacement surgery?
Not reliably. They are more likely to have a role in earlier-stage disease. When arthritis is severe, joint replacement may be the appropriate treatment, and regenerative injections are not a substitute for it.
Are the injections safe?
PRP uses your own blood and has a favourable safety profile in the literature. As with any injection there are risks, and safety over the long term is still being studied, which is why individual assessment matters.
How long before I might notice a difference?
Responses vary between individuals and are not guaranteed. Any expected timeline should be discussed during a clinical assessment based on your specific joint and stage of disease.
Is this suitable for an older relative with severe arthritis?
Possibly not. Advanced, bone-on-bone arthritis is generally better addressed through established care, including surgery where indicated. An assessment is the only way to know what is appropriate.
I have a recent sports injury rather than arthritis — is this the right article?
Acute athletic injuries are a different clinical situation. For the performance and acute-injury angle, see our sports injury programme for athletes, linked above.
Do you offer these treatments at both Holina campuses?
Yes. PRP therapy and stem cell therapy are available on-site at our Koh Phangan and Khao Yai campuses, following an individualised diagnostic assessment.
How do I start?
The first step is a clinical assessment, including imaging and a review of previous treatments. From there we discuss whether a regenerative approach is a reasonable option for you.
Clinically reviewed by Dr. Natalie Lindemann — Clinical Director, Holina Global · Last reviewed 20 July 2026.
